if for example BD1 licensed the use of AI tech from LBT, a module could feasibly be approved in months & then on licensed to VHT (breast density software provider covering 32% of the US market), the roll out to the majority of US women could be quite seamless - and if they are able to improve the histopatholgy accuracy to 100% (from between 50-75%) this is huge huge. all of the LBT modules work by identifying positives and having a human pathologist review. the academic journals discussing the mis classification on histopatholgy breast samples recommend samples are reviews always by 2 pathologists however - this is limited by availability of pathologist time.
if for example BD1 licensed the use of AI tech from LBT, a...
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
59.5¢ |
Change
0.030(5.31%) |
Mkt cap ! $66.16M | |||
| Open | High | Low | Value | Volume |
| 57.0¢ | 60.5¢ | 57.0¢ | $21.86K | 36.93K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1009 | 58.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 60.0¢ | 11650 | 6 |
View Market Depth
| Last trade - 12.34pm 10/07/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |